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Abstract
Behçet’s disease (BD) is a chronic inflammatory disease 
affecting multiple organ systems, such as the skin, 
joints, blood vessels, central nervous system, and gas-
trointestinal tract. Intestinal BD is characterized by in-
testinal ulcerations and gastrointestinal symptoms. The 
medical treatment of intestinal BD includes corticoste-
roids and immunosupressants. There have been several 
reports of tumor necrosis factor-α (TNF-α) blockers 
being successful in treatment of refractory intestinal 
BD. Here, we report on a patient who was diagnosed 
with intestinal BD despite treatment with the fully hu-
manized TNF-α blocker (adalimumab) for underlying 
ankylosing spondylitis. This patient achieved clinical re-
mission and complete mucosal healing through the ad-
dition of a steroid and azathioprine to the adalimumab 
regimen. 
© 2013 Baishideng. All rights reserved.
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Core tip: Here, we report on a patient who was diag-
nosed with intestinal Behçet’s disease despite treat-
ment with the fully humanized tumor necrosis factor-α 
blocker (adalimumab) for underlying ankylosing spon-
dylitis. This patient achieved clinical remission and com-
plete mucosal healing through the addition of a steroid 
and azathioprine to the adalimumab regimen.
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INTRODUCTION
Behçet’s disease (BD) involves multiple organ systems, 
such as the skin, joints, blood vessels, central nervous 
system, and gastrointestinal (GI) tract[1]. Intestinal BD is 
characterized by intestinal ulcerations and gastrointestinal 
symptoms[2]. The incidence of  BD involving the GI tract 
varies by country, ranging from 3% to 60% of  cases of  
BD[3]. GI bleeding and perforation can be associated with 
intestinal BD, with resultant comorbidities[1]. The medi-
cal treatment for intestinal BD includes corticosteroids 
and immunosupressants. Unfortunately, surgical treat-
ment, such as ileocecal resection, is sometimes necessary 
for intestinal BD with perforation, intractable pain, and 
hemorrhage which are refractory to conventional thera-
py[4]. There have been several reports of  tumor necrosis 
factor-α (TNF-α) blockers being successful in refractory 
intestinal BD. Most of  these reported on the efficacy 
of  infliximab[4-9] and a few reported on the efficacy of  
adalimumab[10,11]. Here, we report on a patient who was 
diagnosed with intestinal BD despite being treated with 
the fully humanized TNF-α blocker (adalimumab) for 
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underlying ankylosing spondylitis. This patient achieved 
and maintained clinical remission and complete mucosal 
healing through the addition of  a steroid and azathio-
prine to the adalimumab regimen for 43 mo. 
CASE REPORT
A 29-year-old male patient was hospitalized due to severe 
right lower quadrant abdominal pain for the preceding 15 d. 
He had experienced recurrent oral ulcerations and ar-
thralgia for 15 years and had had an erythematous papule 
on his back for the past 2 years. He had undergone ap-
pendectomy for appendicitis 17 years ago. He was diag-
nosed with ankylosing spondylitis 2 years ago because of  
lower back and shoulder pain. He had taken salazopyrine 
1000 mg for 2 mo and had been injected with infliximab 
for his ankylosing spondylitis for 9 mo (5 mg/kg intra-
venously at 0, 2 and 6 wk; 5 mg/kg intravenously every 8 
wk). The oral ulcerations, arthralgias, and erythematous 
papule on his back had improved, but his back pain had 
not been improved at that time. Therefore, the infliximab 
had been switched to adalimumab (40 mg subcutaneously 
every 2 wk) since 10 mo ago. On physical examination 
at admission, he appeared acutely ill, and had a blood 
pressure of  120/70 mmHg, a pulse of  84 beats/min, a 
respiratory rate of  24 breaths/min, and a temperature 
of  36.5  ℃. The abdomen was flat with direct tenderness 
in the right lower quadrant. Bowel sounds were normal. 
The results of  laboratory tests showed a white blood 
cell count (WBC) of  20930/mm3; hemoglobin, 13.9 
g/dL; hematocrit, 41.7%; platelet count, 282000/mm3; 
total protein, 7.2 g/dL; erythrocyte sedimentation rate 
increased to 33 mm/h; and C-reactive protein increased 
to 111 mg/L. A colonoscopy performed on admission 
showed a well-demarcated, large, deep ulcer with an 
exudate, mucosal edema, and erythema at the terminal 
ileum (Figure 1A-C). Colonic biopsies at the terminal il-
eum showed an ulcer with a necroinflammatory exudate. 
On computed tomography, bowel wall thickening and 
prominent enhancement with surrounding fat infiltration 
were noted at the terminal ileum and cecum, suggesting 
active inflammation (Figure 2). Finally he was diagnosed 
as intestinal BD according to the clinical symptoms and 
examination. The disease activity index for intestinal Be-
hçet’s disease (DAIBD) was 90, reflecting severe disease 
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Figure 1  A colonoscopy on admission revealed a large, deep, well-demarcated ulcer with exudate, mucosal edema and erythema at the terminal ileum (A-C). 
On follow-up colonoscopy at 36 mo, the ulcer at the terminal ileum was replaced by normal mucosa (D-F) with complete mucosal healing. 
Figure 2  In computed tomography, arrow showed bowel wall thickening 
and prominent enhancement with surrounding fat infiltration at the termi-
nal ileum and cecum. This was suggestive of active inflammation. 
activity[12]. Subsequently, the patient was treated with 
conventional medical therapy, including azathioprine 150 
mg and 5-aminosalicylate (5-ASA, Pentasa) 3000 mg/d. 
His abdominal pain seemed to decrease after 10 d. How-
ever, the patient’s severe right lower quadrant abdominal 
pain recurred after one month. The DAIBD score at the 
time of  recurrent abdominal pain was 80, again reflect-
ing severe disease activity[12]. In the early stages of  treat-
ment, clinical remission could not be obtained through 
combination therapy with azathioprine and 5-ASA. Thus, 
at the time of  abdominal pain recurrence, intravenous 
hydrocortisone (300 mg/d) was administrated. Then the 
abdominal pain was improved 2 d after steroid injection. 
Intravenous hydrocortisone was slowly tapered to oral 
prednisolone for 2 mo. Finally, DAIBD score was 10. A 
follow-up colonoscopy after 36 mo demonstrated that 
the ulcer at the terminal ileum was replaced by normal 
mucosa (Figure 1D-F) with complete mucosal healing. 
Combination therapy with azathioprine, 5-ASA and adali-
mumab was continued for 43 mo with clinical and endo-
scopic remission. 
DISCUSSION
We reported on a 29-year-old man with BD and ankylos-
ing spondylitis who developed intestinal BD despite con-
tinuous use of  adalimumab. We treated this patient with 
intravenous steroids to induce clinical remission and with 
azathioprine and 5-ASA for maintenance of  remission. 
This case is unique in two ways. First, the terminal ileal 
ulcer characteristic of  intestinal BD appeared while the 
patient was receiving adalimumab for ankylosing spon-
dylitis. Second, mucosal healing was achieved and main-
tained through combination therapy with azathioprine 
and 5-ASA after induction of  remission with intravenous 
steroids. 
Conventional therapies such as mesalamine, cortico-
steroids, immunosuppressive agents, thalidomide, bowel 
rest, and total parenteral nutrition have been used in the 
treatment of  intestinal BD[13]. However, in patients with 
intestinal BD unresponsive to conventional therapies, 
TNF-α blockers have been shown to improve symp-
toms[12]. Both infliximab and adalimumab can be used for 
treatment of  intestinal BD because they are similar active 
biologics, monoclonal antibodies to TNF-α[10,11,14]. There 
has been no data available regarding the comparative ef-
ficacy of  infliximab and adalimumab in intestinal BD. In 
Table 1 there have been many publications reporting on 
the effectiveness of  infliximab[4-9]. However, there have 
been only a few reports of  the efficacy of  adalimumab 
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Table 1  Clinical characteristics of patients with intestinal Behçet’s disease receiving infliximab or adalimumab
Case Age (yr)/
gender
Duration of 
disease (yr)
Anti TNF-α Ab 
for induction 
Previous therapies Maintenance therapy Outcomes Follow-up duration after 
achieving remission
Ref.
1 32/F   5 IFX Steroids IFX Remission 9 mo [14]
6-MP 6-MP
2 37/F   2 IFX Mesalamine IFX Remission 16 mo [14]
Steroids 6-MP
6-MP
3 51/M   4 IFX Steroids IFX Remission 3 yr [14]
Methotrexate
4 38/M   5 IFX Steroids IFX Remission 10 mo [14]
Colchicines
Cyclosporine A
5 43/F   6 IFX Steroids AZA Surgery 6 mo [14]
Azathioprine
6 38/M   3 IFX Steroids IFX Remission 2 yr [14]
6-MP 6-MP
7 35/F Over 20 IFX Steroids Methotrexate Relapse 8 mo1 [7]
Azathioprine
8 27 /F   2 IFX Steroids Steroids Remission 17 mo [5]
Thalidomide Thalidomide
9 30 /F   3 IFX Steroids Thalidomide Relapse 10 mo1 [5]
Colchicines
Cyclosporine
10 42/M 11 IFX Steroids - Remission 1 wk [9]
Colchicine
11 47/M 20 IFX Sulfasalazine - Remission 12 mo [4]
Steroids
Azathioprine
12 30/F - IFX Steroids IFX Remission 22 mo [10]
Azathioprine Switch to adalimumab 
13 45/F   9 IFX Mesalamine IFX Remission 25 wk [6]
Steroids
6-MP
1Duration between remission stage and the first relapse stage after infusion of anti tumor necrosis factor-α antibody (anti TNF-α Ab). F: Female; M: Male; 
IFX: Infliximab; 6-MP: 6-mercaptopurine. 
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in treating intestinal BD[10,11]. Infliximab with combina-
tion therapies, such as 5-ASA and immunosuppressants, 
in patients with intestinal BD is effective for the induc-
tion and maintenance of  remission[4-9,11,14]. In the case of  
adalimumab, adalimumab was reported to be effective 
in inducing complete remission as monotherapy[10]. We 
suggest three reasons why this patient may have devel-
oped an ulcer of  the terminal ileum during the use of  
adalimumab, but not during the use of  infliximab. First, 
the two medicines have different routes of  injection, with 
adalimumab injected subcutaneously (SQ) and infliximab 
injected intravenously. When infliximab is injected intra-
venously, it enters the venous circulation directly with 
100% bioavailability and no absorption phase, thereby 
reaching a more rapid therapeutic range than achieved 
with subcutaneous injection. Conversely, the bioavailabil-
ity of  an adalimumab 40 mg SQ dose has been estimated 
as 64%[15]. Second, there might be a difference in the ef-
fective dose between adalimumab and infliximab. Adalil-
mumab is used to be injected as fixed dose irrespective 
of  body weight (40 mg subcutaneously every 2 wk) but 
infliximab is used to be injected according to the body 
weight (5 mg/kg at 0, 2 and 6 wk; 5 mg/kg every 8 wk). 
Compared to the infliximab, adalilmumab in fixed dose 
was supposed to be less effective in this patient with 22.8 
kg/m2 body mass index because of  shortage of  dose. 
Third, intravenous injection might be more potent than 
subcutaneous injection because BD is characterized by 
systemic vasculitis[16]. Infliximab and adalimumab are dif-
ferent medicines having unique pharmacokinetics. There 
was no head to head study for comparing effectiveness 
of  infliximab and adalimumab. Further studies are war-
ranted to compare the efficacy of  adalimumab and inflix-
imab in patients with intestinal BD.
In conclusion, this is the first case report of  intestinal 
BD appearing despite the use of  adalimumab. Further-
more, the subject in this case improved with the con-
ventional combination of  intravenous steroids for the 
induction of  remission and azathioprine and 5-ASA for 
maintenance of  remission. Despite the use of  adalim-
umab, a conventional combination of  therapies including 
intravenous steroids, azathioprine, and 5-ASA might be 
important in treating patients with intestinal BD.
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